Header Logo

Connection

Yehuda Handelsman to Blood Glucose

Back to Details
This is a "connection" page, showing publications Yehuda Handelsman has written about Blood Glucose.
Yehuda Handelsman
Connection Strength
4.619
Blood Glucose
  1. Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S14-S29.
    View in: PubMed
    Score: 0.550
  2. Diabetes treatment over age 65: Is worse control really better? J Diabetes. 2017 May; 9(5):428-430.
    View in: PubMed
    Score: 0.496
  3. Lessons from glargine trials: what is the goal fasting glucose with basal insulin? J Diabetes. 2014 Jul; 6(4):271-3.
    View in: PubMed
    Score: 0.406
  4. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocr Pract. 2010 Jul-Aug; 16(4):617-28.
    View in: PubMed
    Score: 0.312
  5. The use of the bile acid sequestrant colesevelam HCl in patients with type 2 diabetes mellitus: for glucose and lipid control. Introduction. Postgrad Med. 2009 May; 121(3 Suppl 1):5-6.
    View in: PubMed
    Score: 0.288
  6. Sodium-glucose cotransporter 2 inhibitors for macroalbuminuria: A new indication. J Diabetes. 2020 Jan; 12(1):8-9.
    View in: PubMed
    Score: 0.149
  7. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes. Adv Ther. 2019 10; 36(10):2567-2586.
    View in: PubMed
    Score: 0.147
  8. Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019 04; 21(4):883-892.
    View in: PubMed
    Score: 0.141
  9. Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes. J Diabetes Complications. 2019 03; 33(3):236-242.
    View in: PubMed
    Score: 0.140
  10. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY 2018 POSITION STATEMENT ON INTEGRATION OF INSULIN PUMPS AND CONTINUOUS GLUCOSE MONITORING IN PATIENTS WITH DIABETES MELLITUS. Endocr Pract. 2018 Mar; 24(3):302-308.
    View in: PubMed
    Score: 0.133
  11. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017 12; 5(12):941-950.
    View in: PubMed
    Score: 0.129
  12. Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with =5% weight loss. Postgrad Med. 2016 Nov; 128(8):740-746.
    View in: PubMed
    Score: 0.121
  13. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY 2016 OUTPATIENT GLUCOSE MONITORING CONSENSUS STATEMENT. Endocr Pract. 2016 Feb; 22(2):231-61.
    View in: PubMed
    Score: 0.115
  14. Proceedings from the American Association of Clinical Endocrinologists and American College of Endocrinology consensus conference on glucose monitoring. Endocr Pract. 2015 May; 21(5):522-33.
    View in: PubMed
    Score: 0.109
  15. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care. 2014 Oct; 37(10):2723-30.
    View in: PubMed
    Score: 0.103
  16. Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-na?ve patients with type 2 diabetes. Diabetes Obes Metab. 2014 Sep; 16(9):869-72.
    View in: PubMed
    Score: 0.101
  17. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab. 2014 Jul; 16(7):636-44.
    View in: PubMed
    Score: 0.100
  18. Comprehensive diabetes cardiovascular treatment = sugar + blood pressure + lipids. J Diabetes. 2011 Dec; 3(4):257-60.
    View in: PubMed
    Score: 0.086
  19. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract. 2010 Jul-Aug; 16(4):629-40.
    View in: PubMed
    Score: 0.078
  20. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab. 2010 May; 12(5):384-92.
    View in: PubMed
    Score: 0.077
  21. Colesevelam HCl improves fasting plasma glucose and lipid levels in patients with prediabetes. Postgrad Med. 2009 Nov; 121(6):62-9.
    View in: PubMed
    Score: 0.075
  22. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009 Sep-Oct; 15(6):540-59.
    View in: PubMed
    Score: 0.074
  23. The role of colesevelam HCl in type 2 diabetes mellitus therapy. Postgrad Med. 2009 May; 121(3 Suppl 1):19-24.
    View in: PubMed
    Score: 0.072
  24. Hypoglycemia in the intensive care unit. Curr Opin Clin Nutr Metab Care. 2007 Mar; 10(2):193-6.
    View in: PubMed
    Score: 0.062
  25. Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial. BMJ. 2024 10 15; 387:e080122.
    View in: PubMed
    Score: 0.053
  26. Cardio-renal-metabolic disease in primary care setting. Diabetes Metab Res Rev. 2024 Mar; 40(3):e3755.
    View in: PubMed
    Score: 0.050
  27. American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus. Endocr Pract. 2021 06; 27(6):505-537.
    View in: PubMed
    Score: 0.042
  28. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY. Endocr Pract. 2020 01; 26(1):107-139.
    View in: PubMed
    Score: 0.038
  29. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY. Endocr Pract. 2019 01; 25(1):69-100.
    View in: PubMed
    Score: 0.035
  30. EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES. Endocr Pract. 2019 Feb; 25(2):144-155.
    View in: PubMed
    Score: 0.035
  31. DYSGLYCEMIA-BASED CHRONIC DISEASE: AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS POSITION STATEMENT. Endocr Pract. 2018 Nov; 24(11):995-1011.
    View in: PubMed
    Score: 0.035
  32. Burden of Illness in Type 2 Diabetes Mellitus. J Manag Care Spec Pharm. 2018 Sep; 24(9-a Suppl):S5-S13.
    View in: PubMed
    Score: 0.034
  33. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA. 2017 Jul 04; 318(1):45-56.
    View in: PubMed
    Score: 0.032
  34. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY. Endocr Pract. 2015 Dec; 21(12):1403-14.
    View in: PubMed
    Score: 0.028
  35. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015 Apr; 21(4):438-47.
    View in: PubMed
    Score: 0.027
  36. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type?2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med. 2013 Nov; 30(11):1298-304.
    View in: PubMed
    Score: 0.024
  37. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012 Dec; 35(12):2464-71.
    View in: PubMed
    Score: 0.023
  38. Clinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes. Postgrad Med. 2012 Jul; 124(4):14-20.
    View in: PubMed
    Score: 0.022
  39. Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US. J Diabetes. 2011 Mar; 3(1):67-73.
    View in: PubMed
    Score: 0.020
  40. Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract. 2007 May-Jun; 13(3):260-8.
    View in: PubMed
    Score: 0.016
  41. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007 May-Jun; 13 Suppl 1:1-68.
    View in: PubMed
    Score: 0.016
  42. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract. 2006 Jan-Feb; 12 Suppl 1:6-12.
    View in: PubMed
    Score: 0.014
  43. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003 May-Jun; 9(3):237-52.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.